SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-263021
Filing Date
2022-10-14
Accepted
2022-10-14 17:00:07
Documents
12
Period of Report
2022-10-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d353740d8k.htm   iXBRL 8-K 30606
  Complete submission text file 0001193125-22-263021.txt   156177

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cadl-20221013.xsd EX-101.SCH 2862
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20221013_lab.xml EX-101.LAB 18740
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20221013_pre.xml EX-101.PRE 11712
6 EXTRACTED XBRL INSTANCE DOCUMENT d353740d8k_htm.xml XML 3548
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 221311881
SIC: 2836 Biological Products, (No Diagnostic Substances)